Navigation Links
AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Date:11/27/2007

e to begin marketing the first version of this test in the United States and certain international markets in 2008."

About AppyScore and the Need for a New Method of Diagnosing Appendicitis

AspenBio's AppyScore is the first blood-based Screen/Triage Test for human appendicitis. An estimated 5% to 7% of the world's population will get appendicitis in their lifetime. Annually, in the U.S. alone, an estimated 6 million patients enter hospital emergency rooms (ERs) complaining of abdominal pain, and who could potentially have appendicitis. Upon entering the ER, the current standard of care for these patients is to draw blood and urine samples, take vital signs and complete an initial physical health examination. Depending upon the results and clinical impression of the ER physician, a computed tomography (CT) scan may also be scheduled to assist in the diagnosis or rule out of appendicitis. CT scans generally take several hours to schedule and complete the procedure, and interpret the results. Moreover, CT scans are expensive, costing $1,500 to $3,000 each, and subject patients (mostly children and adolescents) to high levels of ionizing radiation.

Based upon the current standard of care, an estimated 700,000 patients in the U.S. are diagnosed with appendicitis and have their appendixes surgically removed. However, an estimated 1 in 5 to 1 in 7 (14% to 20%) appendectomy surgeries remove a normal appendix due to an incorrect diagnosis. This would mean more than a 100,000 unnecessary surgeries occur every year at a great cost to patients, insurance companies and create unnecessary pain, suffering and risk to human life and possibly other ongoing patient health issues.

Not properly detecting real cases of appendicitis is also a major problem. A large independent research report (Graff et al., 2000 Acad Emerg Med Vol 7 n 11 pp 1244-55) of approximately 1,026 appendicitis patients from 12 hospitals across the northeastern United States reported th
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AspenBio Pharma Reports Second Quarter 2007 Results
2. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
3. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
4. AspenBio Pharma to Present the Edgewater Research Investor Conference
5. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
6. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
7. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
10. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 Global Stem Cells ... with Shenzhen HANK Bioengineering Co., Ltd. and its ... will establish a stem cells training course in ... September 2015. , Shenzhen HANK is a biotechnology ... scientist, microbiologist and virologist, to integrate research, development, ...
(Date:2/28/2015)... Increasing its efforts to resolve the ... three episodes of The GMO TRUTH podcast on both ITunes ... it continues its mission to discover the truth and change ... to “uncover the truth about the GMOs in our food ... Truth Podcast is an expansion of the documentary/investigative film-making methodology ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Nova Scotia (PRWEB) February 27, 2015 ... stage vaccine and immunotherapy company, today announced that ... its application for Fast Track designation and Phase ... vaccines, in conjunction with the mutual co-development agreement ... previously obtained Fast Track designation for the DPX-Survivac. ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... , ... assay • LEADseeker • SPA Imaging Beads, ... present in high levels in the pituitary and are processed into ... and β-endorphin. The various melanocyte stimulating hormones are known to activate ...
... , ... kinase assay • LEADseeker • chemiluminescence , , ... least 500 kinase and phosphatase enzymes exist, their activities having ... cascade in disease pathways such as inflammation and cancer, so ...
... , ... workspace • base set • differential expression analysis • principal components ... , ... advanced statistics on samples from a study on human ovarian cancer. ...
Cached Biology Technology:The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 5Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 2Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 3Performance of the AMARA HitHunter Chemiluminescence Kinase Assay with the LEADseeker Multimodality Imaging System 4Extended data analysis using DeCyder EDA 2Extended data analysis using DeCyder EDA 3Extended data analysis using DeCyder EDA 4Extended data analysis using DeCyder EDA 5Extended data analysis using DeCyder EDA 6Extended data analysis using DeCyder EDA 7Extended data analysis using DeCyder EDA 8Extended data analysis using DeCyder EDA 9Extended data analysis using DeCyder EDA 10
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... /PRNewswire-iReach/ -- Over the past several weeks and months there ... sites that discuss Pro Ana in any form or that ... like that promote dangerous conditions such as anorexia and bulimia, ... ) The premise is that they encourage, support ...
... YORK, JULY 10, 2013 Researchers at Memorial ... have developed a new method for identifying the ... within multicellular environments. The technique, named ... (CTAP), exploits the inability of vertebrate cells to ...
... depleting the Earth,s supply of oil are unwarranted, according to ... as opposed to the supply will reach its own ... painted pictures of everything from a calm development of alternatives ... world reaches its peak of oil production and then ...
Cached Biology News:Pro Ana and Thinspiration Sites Under Attack 2Pro Ana and Thinspiration Sites Under Attack 3Stanford researchers say 'peak oil' concerns should ease 2Stanford researchers say 'peak oil' concerns should ease 3
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Request Info...
... Printing Kit contains choice of Printing Surface (3 glass ... Ti adhesion layer, 1 silicon wafer coated with 1000 ... plain glass slides) and PDMS Stamps (3 PDMS micropatterned ... or 100 um x 10 mm or 200 um ...
LTBP-1 (E-20)...
Biology Products: